Liminatus Pharma Stock Soars 38.02% on Digital Asset Exploration

On July 24, 2025, Liminatus Pharma's stock surged by 38.02% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Liminatus Pharma, a pre-clinical-stage immuno-oncology company, has been exploring digital assets for its treasury management. This strategic move comes as the company's stock has declined over 50% in the past six months, indicating a potential shift in its financial strategy to stabilize and grow its market position.

The company's recent initiatives and strategic decisions have been closely watched by the market, as investors seek to understand the underlying factors driving the stock's volatility. The exploration of digital assets suggests a forward-thinking approach to financial management, which could potentially attract new investors and stabilize the company's financial outlook.